377 PLANTATION STREET, WORCESTER, MA
Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Regains Compliance with Nasdaq Capital Market Requirement
Completing Asset Acquisition or Sale, Other Events
Shareholder votes
Material disclosure
Material Contracts, Other Events
Announces Reverse Stock Split
Q2
Q1
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Post-Effective Amendment
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Post-Effective Amendment to Registration Statement